Frequently Asked Questions
Who is required to file a Beneficial Ownership Information (BOI) report under the CTA?
Most businesses, including corporations, LLCs, LLPs, and other entities formed by filing with a Secretary of State, must file a BOI report unless they qualify for an exemption. Exempt entities include publicly traded companies, banks, credit unions, insurance companies, securities brokers, and large operating companies with over 20 full-time employees, an operating presence in the U.S., and sales exceeding $5 million.
What information must be included in a BOI report?
A BOI report must include details about the entity's beneficial owners, defined as individuals who own or control 25% or more of the entity or exercise substantial control. Required information for each beneficial owner includes their name, date of birth, address, and a photograph of a government-issued ID.
What are the deadlines for filing a BOI report?
Entities formed before January 1, 2024, must file their initial BOI report by January 1, 2025. Entities created on or after January 1, 2024, must file their BOI report within 90 days of formation. Additionally, any changes to the reported information must be updated within 90 days.
Under the Corporate Transparency Act (CTA)
Beginning January 1, 2024, the Corporate Transparency Act (CTA) imposed new disclosure requirements on businesses. The CTA requires most businesses to report information about the owners of the business to the Treasury’s Financial Crimes Enforcement Network (FinCen). Below are some of the highlights of this new law.
The CTA requires corporations, LLCs, LLPs and other entities formed by filing a document with a Secretary of State to file a Beneficial Ownership Information (BOI) report with FinCEN, unless the entity qualifies for an exemption. Entities that are not exempt from the CTA are called “domestic reporting companies”.
There are many different types of businesses that are exempt from filing under the CTA. Most of these exemptions apply to businesses that already have significant federal or state reporting obligations. Entities that are exempt include publicly traded companies, banks, credit unions, insurance companies and securities brokers. There is also an exemption for large operating companies that (i) have more than 20 full-time employees, (ii) have an operating presence in the U.S., and (iii) have sales exceeding $5 million.
For entities created before January 1, 2024, the BOI report must include information about the business and its beneficial owners. For entities created on or after January 1, 2024, the BOI report must also include information about the entity’s applicants.
The BOI report must include certain information about the entity’s “beneficial owners”. Beneficial owners include anyone who, directly or indirectly, either owns or controls 25% or more of the entity or who exercises substantial control over the entity. The information reported to FinCEN for each beneficial owner must include their name, date of birth, address and a photograph of a government issued ID.
For entities formed before January 1, 2024, the initial BOI report must be filed by January 1, 2025. For entities formed after January 1, 2024, the initial BOI report must be filed with 90 days of the entity’s creation. If the information reported on a BOI report changes, an updated report must be filed with 90 days.
MORE ARTICLES BY CATEGORY
The 2025 Healthcare Fraud Takedown Is a Warning Shot for Wound Care Providers
Wound care is now an enforcement priority. The 2025 fraud takedown targets skin substitute billing, graft utilization, and Medicare compliance.
Read More >>FDA and Novo’s Uncharted Waters to Exert Pressure on Hims & Hers and GLP-1 Compounders
Novo’s lawsuit against Hims & Hers, coupled with FDA’s referral to the DOJ, marks a direct escalation against 503A compounded semaglutide. If your pharmacy dispenses, compounds, or markets GLP-1 therapies, this is not a headline, it is a regulatory turning point.
Read More >>What Wells Pharma v. Zyla Life Sciences Means for Compounding Pharmacies and Outsourcing Facilities
A pending Supreme Court case could reshape how compounding pharmacies face litigation under state unfair competition laws tied to FDA approval standards.
Read More >>Health Law Alliance Welcomes Compounding Expert Pharmacist-Attorney Dr. Martha Rumore as Of Counsel
Health Law Alliance adds powerhouse Pharmacist/Attorney Dr. Martha Rumore to their team of boutique healthcare attorneys.
Read More >>
